rs1862513 — RETN -420C>G

Resistin's Hidden Switch — The Promoter Variant That Turns Up Inflammation

Resistin is an adipokine — a signaling molecule secreted primarily by macrophages in human adipose tissue — that acts as a brake on insulin action and an accelerator of inflammation. Unlike in rodents where it comes from fat cells directly, human resistin is mainly produced by macrophages infiltrating adipose tissue¹¹ macrophages infiltrating adipose tissue
This macrophage origin makes human resistin more of an inflammatory signal than a pure metabolic hormone, linking metabolic dysfunction to chronic low-grade inflammation. The rs1862513 -420C>G polymorphism sits in the RETN gene's promoter region and acts as a molecular volume knob: the G allele turns the gene up, increasing resistin production and widening its downstream consequences for insulin sensitivity, liver fat, and cardiovascular risk.

The Mechanism

The -420 position in the RETN promoter is a binding site for two transcription factors, Sp1 and Sp3²² Sp1 and Sp3
Specificity protein 1 and 3 — zinc-finger transcription factors that activate many housekeeping and metabolic genes by binding GC-rich promoter elements. The C allele at this position does not permit this binding. The G allele creates the binding motif that allows Sp1 and Sp3 to dock and drive RETN transcription. Laboratory experiments confirmed that overexpression of Sp1 or Sp3 enhanced RETN promoter activity specifically with the -420G allele³³ overexpression of Sp1 or Sp3 enhanced RETN promoter activity specifically with the -420G allele
Not the -420C allele, demonstrating allele- specific promoter activation. The result is measurably higher fasting serum resistin in G allele carriers, with the GG genotype showing the highest levels. Higher resistin impairs insulin signaling in muscle and liver, promotes hepatic fat deposition, and stimulates inflammatory cytokines including TNF-alpha and IL-6.

The Evidence

The functional discovery by Osawa et al. 2004⁴⁴ Osawa et al. 2004
Osawa H et al. The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Diabetologia, 2004 in a Japanese cohort identified the GG genotype as associated with T2DM (adjusted OR 1.97) and found it could accelerate disease onset by 4.9 years. The association with resistin levels was independently confirmed in the Framingham Offspring Study⁵⁵ Framingham Offspring Study
Hivert MF et al. 2009 — 2,531 participants followed for 28 years, where the -420C/G association with plasma resistin remained significant (P = 0.0009) in combined meta-analysis, though with high heterogeneity across studies.

A 2022 meta-analysis⁶⁶ 2022 meta-analysis
Zhao X et al. Frontiers in Endocrinology, 2022 — 23 case-control studies, 10,651 T2DM cases and 14,366 controls found no overall T2DM association, but detected a strong age-modifying effect: in patients under 50, the GG genotype carried substantially elevated diabetes risk (OR 3.14-4.76), while in those over 50 it appeared neutral or slightly protective — a striking finding that may reflect survivor bias, population heterogeneity, or differential expression at different life stages. This age interaction warrants further study.

Beyond diabetes, the GG genotype is associated with non-alcoholic fatty liver disease⁷⁷ non-alcoholic fatty liver disease
NAFLD case-control study: GG vs CC OR 2.3, 95% CI 1.1-4.8 and with colorectal and breast cancer risk in Caucasians⁸⁸ colorectal and breast cancer risk in Caucasians
Meta-analysis of 9 studies (1,951 cases): dominant model OR 1.19, 95% CI 1.05-1.35, consistent with resistin's pro-inflammatory and pro-proliferative signaling properties.

Practical Actions

The most actionable finding is that GG carriers respond more strongly to dietary and pharmacological interventions that lower resistin. Two hypocaloric diet trials in obese Caucasians found that GG carriers showed significantly greater reductions⁹⁹ GG carriers showed significantly greater reductions
Insulin decreased -5.6 vs -2.9 mUI/L, HOMA-IR decreased -2.5 vs -0.6, glucose decreased -7.2 vs -0.8 mg/dL; all p<0.05 in insulin, HOMA-IR, fasting glucose, and LDL-cholesterol on calorie-restricted diets compared to C allele carriers. This means that despite higher baseline insulin resistance, GG individuals gain more from dietary intervention — a clinically useful reversal of expectations.

The Toon Genome Study¹⁰¹⁰ Toon Genome Study
Tanaka S et al. 2017 — 1,981 Japanese community-dwellers demonstrated that n-3 polyunsaturated fatty acid (PUFA) intake was inversely associated with serum resistin across all genotypes, but the inverse association was strongest in GG carriers¹¹¹¹ strongest in GG carriers
Resistin ranged from 18.9 ng/mL in the lowest n-3 PUFA quartile to 14.5 ng/mL in the highest, p=0.001; genotype-intake interaction p=0.004, with minimal effect in CC carriers. This genotype-specific response to omega-3 intake is directly actionable.

A small pilot study also found that the GG genotype predicted greater response to pioglitazone¹²¹² predicted greater response to pioglitazone
G/G genotype was independent predictor of FPG reduction, P=0.020, and HOMA-IR reduction, P=0.012 — a thiazolidinedione insulin sensitizer — in T2DM patients, suggesting pharmacogenomic relevance worth discussing with a prescribing physician if diabetes medications are being considered.

Monitoring serum resistin, fasting insulin, and HOMA-IR provides direct feedback on how well diet and lifestyle changes are working for GG carriers.

Interactions

The rs3219175 variant (c.-358G>A, also written as SNP-358) in the RETN promoter interacts with rs1862513. Japanese studies show that the G-A haplotype (combining -420G and -358A) produces the highest plasma resistin levels¹³¹³ highest plasma resistin levels
SNP-358 A allele is required for -420G to confer maximum resistin elevation in the Japanese population, greater than either variant alone. For those carrying GG at rs1862513, knowing the rs3219175 genotype provides additional resolution on resistin expression.

The PPARG rs1801282 Pro12Ala variant also interacts with rs1862513: in Japanese populations, PPARgamma Pro/Pro combined with -420 G/G genotype was synergistically associated with higher plasma resistin¹⁴¹⁴ PPARgamma Pro/Pro combined with -420 G/G genotype was synergistically associated with higher plasma resistin
Synergistic interaction detected in a general Japanese community study. Since PPARgamma is the primary transcription factor through which thiazolidinediones work, this interaction may partly explain the genotype-specific pioglitazone response.